Virax Biolabs Group LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Virax Biolabs Group Limited, a biotechnology company focused on T cell in-vitro diagnostics, reported a net loss of $6.07 million for the fiscal year ended March 31, 2025, continuing a trend of substantial operating losses as it invests heavily in its ViraxImmune platform while existing product revenues remain minimal.
NASDAQ
Virax Biolabs Group Limited files its annual report on Form 20-F, detailing its financial performance for the fiscal year ended March 31, 2024, and outlining its strategic focus on T cell in-vitro diagnostics.